Novartis filed a clinical trial application for CTL019 in China on Aug. 12, which has been accepted by the CDE. CTL019 is a breakthrough new CAR T-cell drug under Novartis, which is also the world’s first CAR T-cell therapy approved.
|
[ Search ]
[ ]
[ Email ]
[ Print ]
[ Close ]
[ Top ]
- SunSirs: On February 19th, the Price of Imported Potassium Chloride Fell by 1.80%
- SunSirs: Costs Rose and Supply Increased, DOTP Prices Were Weak Consolidated after the Holiday
- SunSirs: After the Holiday, Plasticizer Manufacturers Resumed Production and DOP Supply Increased
- SunSirs: Costs Rose, Supply Increased, and DBP Prices Weakly Consolidated
- SunSirs: Poor Replenishment, the Price of Aluminum Fluoride Was Temporarily Stable after the Holiday
- SunSirs: On February 18th, the Domestic DBP Market Was Temporarily Stable
- SunSirs: The Price of Tetrachloroethylene Has Fallen Narrowly after the Hholiday, and Expectations A
- SunSirs: Demand Was Weak, Production Was Resumed, and Acetic Anhydride Prices Dropped after the Holi
- SunSirs: Demand Was Weak, Production Was Resumed, and Acetic Anhydride Prices Dropped after the Holi
- SunSirs: China Fuel Oil 180CST Market in 2024 may Maintain a Volatile Trend
|
Date:2019-08-28 Views:576
